Posted on August 02, 2018

Qatar University College of Pharmacy (QU-CPH) MSc graduate Fatima Khalifa Al-Sulaiti won the Best Poster Award in the 2018 American College of Clinical Pharmacy (ACCP) Virtual Poster Symposium.

Fatima’s abstract on the “Outcomes of Peak-trough-based versus Trough-only-based Vancomycin Therapeutic Drug Monitoring Clinical and Pharmacokinetic Approaches: A Pragmatic Randomized Controlled Trial” was selected among hundreds in the ACCP Best Poster competition. She presented her poster to a panel of expert judges.

The posters were evaluated on the following criteria: originality, rationale, and significance; research question, study design, and methods; results; discussion/conclusions; and contribution to the research and response to the judges’ questions. Fatima Al-Sulaiti has been invited to present the winning poster at the 2018 ACCP Global Conference on Clinical Pharmacy in October 2018. The winning poster is a product of Fatima’s MSc research project that was supervised by CPH Associate Professor Dr. Ahmed Awaisu and co-supervised by Dr. Ahmed Nader (AbbVie Inc. Principal Scientist of Pharmacometrics in USA), Dr. Daoud Al-Badriyeh (CPH Associate Professor), and Dr. Hazem Elewa (CPH Assistant Professor).

Commenting on the award, Dr Mohammad Diab, Dean College of Pharmacy said: ‘Aligning with the College mission to promote research and scholarly activity, we are proud to announce the winning of Ms. Fatima Khalifa Al-Sulaiti the best poster award in the 2018 American College of Clinical Pharmacy (ACCP) Virtual Poster Symposium. Her project will, without a doubt, advance healthcare and serve as a pharmacy resource in Qatar and the Middle East. This is a real reflection on the College of Pharmacy research quality and excellence’.

CPH Associate Professor and Main Supervisor Dr Ahmed Awaisu said “We are really proud of Fatima for this significant and tremendous accomplishment. Her project is the first of its kind in Qatar in which the investigators have developed a vancomycin population-specific dosing model for Qatar. This model will allow population-specific calculations of vancomycin pharmacokinetic parameters in individual patients in Qatar’s clinical settings, an important tool in vancomycin dosing and therapy. The project also identified the exact vancomycin monitoring practice deficiencies in the local setting, which will guide health policymakers to establish setting-specific protocols to improve TDM practices in Qatar.”